Brink Biologics is a startup based in the United States.
Brink Biologics is a company headquartered in the United States.
Brink Biologics develops and licenses proprietary NK-92 natural killer cell lines and associated assays for use in antibody-dependent cellular cytotoxicity (ADCC) testing and related immunological research and therapeutic development.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.